OraSure Technologies, Inc. (OSUR) Given Consensus Rating of “Buy” by Analysts
OraSure Technologies, Inc. (NASDAQ:OSUR) has received a consensus recommendation of “Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $15.46.
A number of brokerages have weighed in on OSUR. Canaccord Genuity increased their price target on shares of OraSure Technologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, August 3rd. BidaskClub downgraded shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Stephens reaffirmed an “overweight” rating and set a $19.00 price objective (up from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. Jefferies Group LLC raised their price objective on shares of OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, June 28th. Finally, Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Saturday, May 6th.
Shares of OraSure Technologies (OSUR) traded up 2.12% during midday trading on Friday, hitting $20.73. 571,709 shares of the stock were exchanged. The firm has a market cap of $1.21 billion, a P/E ratio of 38.32 and a beta of 1.57. The stock’s 50 day moving average is $18.32 and its 200 day moving average is $13.99. OraSure Technologies has a 12-month low of $6.84 and a 12-month high of $21.59.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The firm had revenue of $40.18 million during the quarter, compared to the consensus estimate of $36.54 million. During the same period in the prior year, the firm earned $0.07 EPS. The business’s revenue was up 28.1% on a year-over-year basis. On average, equities research analysts forecast that OraSure Technologies will post $0.48 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.watchlistnews.com/orasure-technologies-inc-osur-given-consensus-rating-of-buy-by-analysts/1474936.html.
In other news, EVP Anthony Zezzo II sold 72,916 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $21.26, for a total transaction of $1,550,194.16. Following the completion of the transaction, the executive vice president now directly owns 218,326 shares of the company’s stock, valued at approximately $4,641,610.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jack E. Jerrett sold 73,463 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $20.77, for a total transaction of $1,525,826.51. Following the transaction, the senior vice president now directly owns 81,593 shares of the company’s stock, valued at $1,694,686.61. The disclosure for this sale can be found here. Insiders have sold a total of 1,036,670 shares of company stock valued at $19,807,152 over the last ninety days. 7.80% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in OSUR. BlackRock Inc. increased its position in shares of OraSure Technologies by 127,593.4% in the first quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock valued at $100,123,000 after buying an additional 7,737,261 shares in the last quarter. Norges Bank purchased a new position in shares of OraSure Technologies during the fourth quarter valued at about $9,786,000. Vanguard Group Inc. increased its position in shares of OraSure Technologies by 30.3% in the first quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock valued at $57,752,000 after buying an additional 1,037,439 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of OraSure Technologies by 22.3% in the first quarter. Renaissance Technologies LLC now owns 5,132,003 shares of the medical instruments supplier’s stock valued at $66,357,000 after buying an additional 934,700 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of OraSure Technologies by 127.2% in the first quarter. JPMorgan Chase & Co. now owns 1,573,586 shares of the medical instruments supplier’s stock valued at $20,347,000 after buying an additional 881,132 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.